In vivo proton magnetic resonance spectroscopy of breast cancer: A review of the literature

Breast Cancer Research

Volumn 14, Issue 2, 2012, Pages

  Begley, Jonathan K P ^a   Redpath, Thomas W ^b   Bolan, Patrick J ^c   Gilbert, Fiona J ^d  

^a UNIVERSITY OF ABERDEEN   (United Kingdom)

^b UNIVERSITY OF ABERDEEN   (United Kingdom)

^c UNIVERSITY OF MINNESOTA MEDICAL SCHOOL   (United States)

^d UNIVERSITY OF CAMBRIDGE   (United Kingdom)

Author keywords

[No Author keywords available]

Indexed keywords

ANTHRACYCLINE; CYCLOPHOSPHAMIDE; DOXORUBICIN; FLUORODEOXYGLUCOSE F 18; GADOLINIUM; GADOLINIUM PENTETATE; GADOLINIUM PENTETATE MEGLUMINE; TAXANE DERIVATIVE; CHOLINE; CONTRAST MEDIUM; DIAGNOSTIC AGENT; PROTON;

ANTINEOPLASTIC ACTIVITY; BREAST CANCER; BREAST EXAMINATION; BREAST LESION; CANCER ADJUVANT THERAPY; IN VITRO STUDY; IN VIVO STUDY; MALIGNANT TRANSFORMATION; MEDICAL LITERATURE; MULTIPLE CYCLE TREATMENT; NUCLEAR MAGNETIC RESONANCE IMAGING; POSITRON EMISSION TOMOGRAPHY; PROTON NUCLEAR MAGNETIC RESONANCE; REVIEW; SENSITIVITY AND SPECIFICITY; SPECTROSCOPY; TISSUE METABOLISM; TREATMENT RESPONSE; TUMOR VOLUME; ADJUVANT THERAPY; BREAST; BREAST TUMOR; FEMALE; HUMAN; METABOLISM; METHODOLOGY; NUCLEAR MAGNETIC RESONANCE SPECTROSCOPY; PATHOLOGY;

BREAST; BREAST NEOPLASMS; CHOLINE; CONTRAST MEDIA; FEMALE; GADOLINIUM; HUMANS; MAGNETIC RESONANCE SPECTROSCOPY; NEOADJUVANT THERAPY; PROTONS;

EID: 84859980074     PISSN: 14655411     EISSN: 1465542X     Source Type: Journal    
DOI: 10.1186/bcr3132     Document Type: Review

References (57)

1. Jemal A, Siegel R, Xu J, Ward E. Cancer statistics 2010. CA Cancer J Clin 2010, 60:277-300. 10.3322/caac.20073, 20610543.
2. Jagannathan NR, Singh M, Govindaraju V, Raghunathan P, Coshic O, Julka PK, Rath GK. Volume localized in vivo proton MR spectroscopy of breast carcinoma: variation of water-fat ratio in patients receiving chemotherapy. NMR Biomed 1998, 11:414-422. 10.1002/(SICI)1099-1492(199812)11:8<414::AID-NBM537>3.0.CO;2-W, 10221584.
3. Roebuck JR, Cecil KM, Schnall MD, Lenkinski RE. Human breast lesions: characterization with proton MR spectroscopy. Radiology 1998, 209:269-275.
4. Kvistad KA, Bakken IJ, Gribbestad IS, Ehrnholm B, Lundgren S, Fjøsne HE, Haraldseth O. Characterization of neoplastic and normal human breast tissues with in vivo 1H MR spectroscopy. J Magn Reson Imaging 1999, 10:159-164. 10.1002/(SICI)1522-2586(199908)10:2<159::AID-JMRI8>3.0.CO;2-0, 10441019.
5. Jagannathan NR, Kumar M, Seenu V, Coshic O, Dwivedi SN, Julka PK, Srivastava A, Rath GK. Evaluation of total choline from in-vivo volume localized proton MR spectroscopy and its response to neoadjuvant chemotherapy in locally advanced breast cancer. Br J Cancer 2001, 84:1016-1022. 10.1054/bjoc.2000.1711, 2363867, 11308247.
6. Huang W, Fisher PR, Dulaimy K, Tudorica LA, O'Hea B, Button TM. Detection of breast malignancy: diagnostic MR protocol for improved specificity. Radiology 2004, 232:585-591. 10.1148/radiol.2322030547, 15205478.
7. Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le CT, Kelcz F, Lechner MC, Luikens BA, Carlson RA, Brandt KR, Amrmi KK, Nelson MT, Everson LI, Emory TH, Tuttle TM, Yee D, Garwood M. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of Observer Performance Study at 4.0 T. Radiology 2005, 236:465-475. 10.1148/radiol.2362040836, 16040903.
8. Baek H, Yu HJ, Chen J, Nalcioglu O, Su M. Quantitative correlation between 1H MRS and dynamic contrast-enhanced MRI of human breast cancer. Magn Reson Imaging 2008, 26:523-531. 10.1016/j.mri.2007.10.002, 2653063, 18060716.
9. Sitter B, Sonnewald U, Spraul M, Fjösne HE, Gribbestad IS. High-resolution magic angle spinning MRS of breast cancer tissue. NMR Biomed 2002, 15:327-337. 10.1002/nbm.775, 12203224.
10. Podo F. Tumour phospholipid metabolism. NMR Biomed 1999, 12:413-439. 10.1002/(SICI)1099-1492(199911)12:7<413::AID-NBM587>3.0.CO;2-U, 10654290.
11. Katz-Brull R, Seger D, Rivenson-Segal D, Rushkin E, Degani H. Metabolic markers of breast cancer: enhanced choline metabolism and reduced choline-ether phospholipid synthesis. Cancer Res 2002, 62:1966-1970.
12. Ting Y-LT, Sherr D, Degani H. Variations in energy and phospholipid metabolism in normal and cancer human mammary epithelial cells. Anticancer Res 1996, 16:1381-1388.
13. Aboagye EO, Bhujwalla ZM. Malignant transformation alters membrane choline phospholipid metabolism of human mammary epithelial cells. Cancer Res 1999, 59:80-84.
14. Drost DJ, Riddle WR, Clarke GD. Proton magnetic resonance spectroscopy in the brain: report of AAPM MR Task Group #9. Med Phys 2002, 29:2177-2197. 10.1118/1.1501822, 12349940.
15. Hu J, Yu Y, Kou Z, Huang W, Jiang Q, Xuan Y, Li T, Sehgal V, Blake C, E Haacke M, Soulen RL. A high spatial resolution 1H magnetic resonance spectroscopic imaging technique for breast cancer with a short echo time. Magn Reson Imaging 2008, 26:360-366. 10.1016/j.mri.2007.07.004, 17904326.
16. Su MY, Baik HM, Yu HJ, Chen JH, Mehta RS, Nalcioglu O. Comparison of choline and pharmacokinetic parameters in breast cancer measured by MR spectroscopic imaging and dynamic contrast enhanced MRI. Technol Cancer Res Treat 2006, 5:401-410.
17. Jacobs MA, Barker PB, Bottomley PA, Bhujwalla Z, Bluemke DA. Proton magnetic resonance spectroscopic imaging of human breast cancer: a preliminary study. J Magn Reson Imaging 2004, 19:68-75. 10.1002/jmri.10427, 14696222.
18. Jacobs MA, Barker PB, Argani P, Ouwerkerk R, Bhujwalla ZM, Bluemke DA. Combined dynamic contrast enhanced breast MR and proton spectroscopic imaging: a feasibility study. J Magn Reson Imaging 2005, 21:23-28. 10.1002/jmri.20239, 15611934.
19. Baek HM, Chen JH, Yu HJ, Mehta R, Nalcioglu O, Su MY. Detection of choline signal in human breast lesions with chemical-shift imaging. J Magn Reson Imaging 2008, 27:1114-1121. 10.1002/jmri.21309, 2613433, 18425841.
20. Danishad KKA, Sharma U, Sah RG, Seenu V, Parshad R, Jagannathan NR. Assessment of therapeutic response of locally advanced breast cancer (LABC) patients undergoing neoadjuvant chemotherapy (NACT) monitored using sequential magnetic resonance spectroscopic imaging (MRSI). NMR Biomed 2010, 23:233-241.
21. Sijens PE, Dorrius MD, Kappert P, Baron P, Pijnappel RM, Oudkerk M. Quantitative multivoxel proton chemical shift imaging of the breast. Magn Reson Imaging 2010, 28:314-319. 10.1016/j.mri.2009.11.004, 20071119.
22. Dorrius MD, Pijnappel RM, Jansen-van der Weide MC, Jansen L, Kappert P, Oudkerk M, Sijens PE. Determination of choline concentration in breast lesions: quantitative multivoxel proton MR spectroscopy as a promising noninvasive assessment tool to exclude benign lesions. Radiology 2011, 259:695-703. 10.1148/radiol.11101855, 21460033.
23. Gribbestad IS, Singstad TE, Nilsen G, Fjøsne HE, Engan T, Haugen OA, Rinck PA. In vivo 1H MRS of normal breast and breast tumors using a dedicated double breast coil. J Magn Reson Imaging 1998, 8:1191-1197. 10.1002/jmri.1880080602, 9848727.
24. Cecil K, Schnall M, Siegelman E, Lenkinski R. The evaluation of human breast lesions with magnetic resonance imaging and proton magnetic resonance spectroscopy. Breast Cancer Res Treat 2001, 68:45-54. 10.1023/A:1017911211090, 11678308.
25. Yeung DKW, Cheung HS, Tse GMK. Human breast lesions: characterization with contrast-enhanced in vivo proton MR spectroscopy-initial results. Radiology 2001, 220:40-46.
26. Kim J, Park S, Lee HM, Lee YH, Sung NK, Chung DS, Kim OD. In vivo 1H-MRS evaluation of malignant and benign breast diseases. Breast 2003, 12:179-182. 10.1016/S0960-9776(03)00012-2, 14659324.
27. Joe BN, Chen VY, Salibi N, Fuangtharntip P, Hildebolt CF, Bae KT. Evaluation of 1H-magnetic resonance spectroscopy of breast cancer pre- and postgadolinium administration. Invest Radiol 2005, 40:405-411. 10.1097/01.rli.0000167125.79212.5d, 15973131.
28. Stanwell P, Gluch L, Clark D, Tomanek B, Baker L, Giuffrè B, Lean C, Malycha P, Mountford C. Specificity of choline metabolites for in vivo diagnosis of breast cancer using 1H MRS at 1.5 T. Eur Radiol 2005, 15:1037-1043. 10.1007/s00330-004-2475-1, 15351906, 15351906.
29. Geraghty PR, van den Bosch MAAJ, Spielman DM, Hunjan S, Birdwell RL, Fong KJ, Stables LA, Zakhour M, Herfkens RJ, Ikeda DM. MRI and 1H MRS of the breast: presence of a choline peak as malignancy marker is related to k21 value of the tumor in patients with invasive ductal carcinoma. Breast J 2008, 14:574-580. 10.1111/j.1524-4741.2008.00650.x, 2842578, 19000051.
30. Baltzer PA, Gussew A, Dietzel M, Rzanny R, Gajda M, Camara O, Reichenbach JR, Kaiser WA. Effect of contrast agent on the results of in vivo 1H MRS of breast tumors - is it clinically significant?. NMR Biomed 2011, 25:67-74.
31. Chen JH, Mehta RS, Baek HM, Nie K, Liu H, Lin MQ, Yu HJ, Nalcioglu O, Su MY. Clinical characteristics and biomarkers of breast cancer associated with choline concentration measured by 1H MRS. NMR Biomed 2011, 24:316-324. 10.1002/nbm.1595, 3075960, 20862660.
32. Bolan PJ, Meisamy S, Baker EH, Lin J, Emory T, Nelson M, Everson LI, Yee D, Garwood M. In vivo quantification of choline compounds in the breast with 1H MR spectroscopy. Magn Reson Med 2003, 50:1134-1143. 10.1002/mrm.10654, 14648561.
33. Sardanelli F, Fausto A, Di Leo G, Nijs RD, Vorbuchner M, Podo F. In vivo proton MR spectroscopy of the breast using the total choline peak integral as a marker of malignancy. AJR Am J Roentgenol 2009, 192:1608-1617. 10.2214/AJR.07.3521, 19457825, 19457825.
34. Redpath TW. Signal-to-noise ratio in MRI. Br J Radiol 1998, 71:704-707.
35. Graham SJ, Stanchev PL, Lloyd-Smith JO, Bronskill MJ, Plewes DB. Changes in fibroglandular volume and water content of breast tissue during the menstrual cycle observed by MR imaging at 1.5 T. J Magn Reson Imaging 1995, 5:695-701. 10.1002/jmri.1880050613, 8748488.
36. Bakken IJ, Gribbestad IS, Singstad TE, Kvistad KA. External standard method for the in vivo quantification of choline-containing compounds in breast tumors by proton MR spectroscopy at 1.5 Tesla. Magn Reson Med 2001, 46:189-192. 10.1002/mrm.1175, 11443726.
37. Haddadin IS, McIntosh A, Meisamy S, Corum C, Styczynski Snyder AL, Powell NJ, Nelson MT, Yee D, Garwood M, Bolan PJ. Metabolite quantification and high-field MRS in breast cancer. NMR Biomed 2009, 22:65-76. 10.1002/nbm.1217, 2628417, 17957820.
38. Meisamy S, Bolan PJ, Baker EH, Pollema MG, Le CT, Kelcz F, Lechner MC, Luikens BA, Carlson RA, Brandt KR, Amrami KK, Nelson MT, Everson LI, Emory TH, Tuttle TM, Yee D, Garwood M. Adding in vivo quantitative 1H MR spectroscopy to improve diagnostic accuracy of breast MR imaging: preliminary results of Observer Performance Study at 4.0 T. Radiology 2005, 236:465-475. 10.1148/radiol.2362040836, 16040903.
39. Ogston KN, Miller ID, Payne S, Hutcheon AW, Sakar TK, Schofield A, Heys SD. A new histological grading system to assess response of breast cancers to primary chemotherapy: prognostic significance and survival. Breast 2003, 12:320-327. 10.1016/S0960-9776(03)00106-1, 14659147.
40. Harry VN, Semple SI, Parkin DE, Gilbert FJ. Use of new imaging techniques to predict tumour response to therapy. Lancet Oncol 2010, 11:92-102. 10.1016/S1470-2045(09)70190-1, 20129132.
41. Semple SIK, Staff RT, Heys SD, Redpath TW, Welch AE, Ahearn TS, Hutcheon AW, Gilbert FJ. Baseline MRI delivery characteristics predict change in invasive ductal breast carcinoma PET metabolism as a result of primary chemotherapy administration. Ann Oncol 2006, 17:1393-1398. 10.1093/annonc/mdl136, 16788001.
42. Rieber A, Brambs HJ, Gabelmann A, Heilmann V, Kreienberg R, Kühn T. Breast MRI for monitoring response of primary breast cancer to neo-adjuvant chemotherapy. Eur Radiol 2002, 12:1711-1719. 10.1007/s00330-001-1233-x, 12111062.
43. Johansen R, Jensen LR, Rydland J, Goa PE, Kvistad KA, Bathen TF, Axelson DE, Lundgren S, Gribbestad IS. Predicting survival and early clinical response to primary chemotherapy for patients with locally advanced breast cancer using DCE-MRI. J Magn Reson Imaging 2009, 29:1300-1307. 10.1002/jmri.21778, 19472387.
44. Meisamy S, Bolan PJ, Baker EH, Bliss RL, Gulbahce E, Everson LI, Nelson MT, Emory TH, Tuttle TM, Yee D, Garwood M. Neoadjuvant chemotherapy of locally advanced breast cancer: predicting response with in vivo 1H MR spectroscopy - a pilot study at 4 T. Radiology 2004, 233:424-431. 10.1148/radiol.2332031285, 15516615.
45. Baek HM, Chen JH, Nie K, Yu HJ, Bahri S, Mehta RS, Nalcioglu O, Su MY. Predicting pathologic response to neoadjuvant chemotherapy in breast cancer by using MR imaging and quantitative 1H MR spectroscopy. Radiology 2009, 251:653-662. 10.1148/radiol.2512080553, 2687529, 19276320.
46. Tozaki M, Sakamoto M, Oyama Y, Maruyama K, Fukuma E. Predicting pathological response to neoadjuvant chemotherapy in breast cancer with quantitative 1H MR spectroscopy using the external standard method. J Magn Reson Imaging 2010, 31:895-902. 10.1002/jmri.22118, 20373434.
47. Tozaki M, Sakamoto M, Oyama Y, O'uchi T, Kawano N, Suzuki T, Yamashiro N, Ozaki S, Sakamoto N, Higa K, Abe S, Ogawa T, Fukuma E. Monitoring of early response to neoadjuvant chemotherapy in breast cancer with 1H MR spectroscopy: comparison to sequential 2-[18F]-fluorodeoxyglucose positron emission tomography. J Magn Reson Imaging 2008, 28:420-427. 10.1002/jmri.21454, 18666159.
48. Lenkinski RE, Wang X, Elian M, Goldberg SN. Interaction of gadolinium-based MR contrast agents with choline: implications for MR spectroscopy (MRS) of the breast. Magn Reson Med 2009, 61:1286-1292. 10.1002/mrm.21937, 19365855.
49. Kawai H, Naganawa S, Satake H, Ishigaki S, Sakurai Y, Mori M, Maruyama K. 1H-magnetic resonance spectroscopy of the breast at 3.0-T: comparison of results obtained before and after administration of gadolinium-based contrast agent. J Magn Reson Imaging 2011, 35:717-722.
50. Tse GM, Cheung HS, Pang LM, Chu WC, Law BK, Kung FY, Yeung DK. Characterization of lesions of the breast with proton MR spectroscopy: comparison of carcinomas, benign lesions, and phyllodes tumors. AJR Am J Roentgenol 2003, 181:1267-1272.
51. Bartella L, Morris EA, Dershaw DD, Liberman L, Thakur SB, Moskowitz C, Guido J, Huang W. Proton MR spectroscopy with choline peak as malignancy marker improves positive predictive value for breast cancer diagnosis: preliminary study. Radiology 2006, 239:686-692. 10.1148/radiol.2393051046, 16603660.
52. Bartella L, Thakur SB, Morris EA, Dershaw DD, Huang W, Chough E, Cruz MC, Liberman L. Enhancing nonmass lesions in the breast: evaluation with proton (1H) MR spectroscopy. Radiology 2007, 245:80-87. 10.1148/radiol.2451061639, 17885182.
53. Tozaki M, Fukuma E. 1H MR spectroscopy and diffusion-weighted imaging of the breast: are they useful tools for characterizing breast lesions before biopsy?. AJR Am J Roentgenol 2009, 193:840-849. 10.2214/AJR.08.2128, 19696300.
54. Bathen TF, Heldahl MG, Sitter B, Vettukattil R, Bofin A, Lundgren S, Gribbestad IS. In vivo MRS of locally advanced breast cancer: characteristics related to negative or positive choline detection and early monitoring of treatment response. MAGMA 2011, 24:347-57. 10.1007/s10334-011-0280-9, 21909791.
55. Baik HM, Su MY, Yu H, Mehta R, Nalcioglu O. Quantification of choline-containing compounds in malignant breast tumors by 1H MR spectroscopy using water as an internal reference at 1.5 T. MAGMA 2006, 19:96-104. 10.1007/s10334-006-0032-4, 16779565.
56. Baek HM, Chen JH, Nalcioglu O, Su MY. Proton MR spectroscopy for monitoring early treatment response of breast cancer to neo-adjuvant chemotherapy. Ann Oncol 2008, 19:1022-1024. 10.1093/annonc/mdn121, 2613189, 18372283.
57. Thakur SB, Brennan SB, Ishill NM, Morris EA, Liberman L, Dershaw DD, Bartella L, Koutcher JA, Huang W. Diagnostic usefulness of water-to-fat ratio and choline concentration in malignant and benign breast lesions and normal breast parenchyma: an in vivo 1H MRS study. J Magn Reson Imaging 2011, 33:855-863. 10.1002/jmri.22493, 21448950.